keyword
MENU ▼
Read by QxMD icon Read
search

Ptcl

keyword
https://www.readbyqxmd.com/read/27911989/a-prospective-cohort-study-of-patients-with-peripheral-t-cell-lymphoma-in-the-united-states
#1
Steven M Horwitz, Lauren C Pinter-Brown, Steven T Rosen, Barbara Pro, Eric D Hsi, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A Bellm, Mark A Acosta, Andrei R Shustov, Ranjana H Advani, Tatyana A Feldman, Mary Jo Lechowicz, Sonali M Smith, Frederick Lansigan, Anil Tulpule, Michael D Craig, John P Greer, Brad S Kahl, Joseph W Leach, Neil Morganstein, Carla Casulo, Steven I Park, Francine M Foss
BACKGROUND: Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein, the authors analyzed treatment patterns and outcomes in a prospectively collected cohort of patients with a new diagnosis of nodal PTCL in the United States. METHODS: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) is a prospective multicenter cohort study designed to identify the most common prevailing treatment patterns used for patients newly diagnosed with PTCL in the United States...
December 2, 2016: Cancer
https://www.readbyqxmd.com/read/27898263/genetic-alterations-affecting-gtpases-and-t-cell-receptor-signaling-in-peripheral-t-cell-lymphomas
#2
Rebecca L Boddicker, Gina L Razidlo, Andrew L Feldman
Peripheral T-cell lymphomas (PTCLs) are rare, heterogeneous tumors with poor response to standard therapy and few targeted treatments available. The identification of mutations in the T-cell receptor (TCR) signaling pathway that either directly or indirectly affect Ras- and Rho-family GTPases is an emerging theme across PTCL subtypes. This review summarizes the role of GTPases in TCR signaling and highlights the constellation of mutations in this pathway among PTCLs. In particular, focus is given to the functional impact of the mutations and opportunities for targeted therapy...
November 29, 2016: Small GTPases
https://www.readbyqxmd.com/read/27885817/serum-ferritin-level-is-a-prognostic-marker-in-patients-with-peripheral-t-cell-lymphoma
#3
S Koyama, S Fujisawa, R Watanabe, M Itabashi, D Ishibashi, Y Ishii, Y Hattori, Y Nakajima, K Motohashi, H Takasaki, R Kawasaki, C Hashimoto, E Yamazaki, H Koharazawa, S Takemura, N Tomita, R Sakai, S Motomura, H Nakajima
INTRODUCTION: The prognostic value of serum ferritin level in patients with peripheral T-cell lymphoma (PTCL) remains unknown. METHODS: We retrospectively analyzed clinical data from 78 consecutive patients with newly diagnosed PTCL that were treated with anthracycline-containing regimens between 1998 and 2011. RESULTS: The patients consisted of 50 males and 28 females with a median age of 64 years (range, 16-83 years). The subtypes of PTCL were 39 PTCL, not otherwise specified and 39 angioimmunoblastic T-cell lymphoma (AITL)...
November 24, 2016: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/27873737/erythroderma-and-non-hodgkin-t-cell-lymphoma-what-else-apart-from-mycosis-fungoides-and-s%C3%A3-zary-syndrome
#4
Alessandro Pileri, Cinzia Pellegrini, Claudio Agostinelli, Vieri Grandi, Annalisa Patrizi, Pier Luigi Zinzani, Nicola Pimpinelli
BACKGROUND: Peripheral T-cell lymphomas, not otherwise specified (PTCL-NOS), are a rare condition characterised by specific histology, nodal presentation, and a poor prognosis. In total, 10-18% of patients present with cutaneous involvement which is regarded as a poor prognostic marker. However, cutaneous PTCL-NOS lesions have been rarely reported in the literature. OBJECTIVES: We sought to describe PTCL-NOS cases characterised by erythrodermic dissemination to the skin...
November 21, 2016: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/27861791/foxp1-is-a-key-regulator-of-quiescence-in-healthy-human-cd3-cd4-t-cells-and-is-constitutively-repressed-in-cd3-cd4-t-cells-from-patients-with-lymphoproliferative-disorders
#5
Soizic Garaud, Florence Roufosse, Pushpamali De Silva, Chunyan Gu-Trantien, Jean-Nicolas Lodewyckx, Hugues Duvillier, Sarah Dedeurwaerder, Martin Bizet, Matthieu Defrance, François Fuks, Françoise Bex, Karen Willard-Gallo
The forkhead box P1 (FOXP1) transcription factor has been shown to regulate the generation and maintenance of quiescent naïve murine T cells. In humans, FOXP1 expression has been correlated with overall survival in patients with peripheral T-cell lymphoma (PTCL), although its regulatory role in T-cell function is currently unknown. We found that FOXP1 is normally expressed in all human leukocyte subpopulations. Focusing on primary human CD4(+) T cells, we show that nuclear expression of FOXP1 predominates in naïve cells with significant downregulation detected in memory cells from blood and tonsils...
November 8, 2016: European Journal of Immunology
https://www.readbyqxmd.com/read/27858107/gemcitabine-dexamethasone-and-cisplatin-gdp-as-salvage-chemotherapy-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma-not-otherwise-specified
#6
Fei Qi, Mei Dong, Xiaohui He, Yexiong Li, Weihu Wang, Peng Liu, Jianliang Yang, Lin Gui, Changgong Zhang, Sheng Yang, Shengyu Zhou, Yuankai Shi
Standard therapeutic options for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified (PTCL-NOS) remain unclear. There are few large cohort studies specifically focused on gemcitabine-based chemotherapy for PTCL-NOS. We retrospectively reviewed patients with relapsed or refractory PTCL-NOS who received salvage GDP (gemcitabine, dexamethasone, and cisplatin) chemotherapy at the Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China, from May 2008 to August 2014...
November 17, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27813438/targeting-histone-deacetylases-in-t-cell-lymphoma
#7
Alison J Moskowitz, Steven M Horwitz
Histone deacetylase inhibitors (HDACi) are epigenetic modifiers with single-agent activity in patients with cutaneous and peripheral T-cell lymphoma (CTCL, PTCL). The mechanisms for this preferential activity remain unclear, and although some would term this as 'class effect,' there are differences in efficacy and safety, likely a result of the varying chemical structures/classes, histone and non-histone targets, potencies, and clinical dosing for each. Three HDACi have single-agent approval in relapsed/refractory TCL in the United States: romidepsin in CTCL and PTCL, vorinostat in CTCL, and belinostat in PTCL...
November 4, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27787356/pegylated-liposomal-encapsulated-doxorubicin-in-cutaneous-composite-lymphoma-a-case-report
#8
Uwe Wollina, Dana Langner, Gesina Hansel, Gunter Haroske
BACKGROUND: Cutaneous composite lymphomas are very rare. Their treatment depends upon the different contributing lymphoma entities. Peripheral T-cell lymphoma, not otherwise specified, (PTCL-NOS) represents an aggressive lymphoma subtype. Follicular cutaneous B-cell lymphoma (FCBCL) runs an indolent course. Treatment with pegylated liposomal encapsulated doxorubicin (PLE-DOXO) has yet not been reported in this entity. CASE PRESENTATION: A 73-year-old male patient presented with 3 rapidly growing, painful nodules on his left leg...
October 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27756777/hiv-infection-and-survival-of-lymphoma-patients-in-the-era-of-highly-active-antiretroviral-therapy
#9
Xuesong Han, Ahmedin Jemal, Erin Hulland, Edgar P Simard, Loretta Nastoupil, Elizabeth M Ward, Christopher R Flowers
BACKGROUND: Highly active antiretroviral therapy (HAART) has extended the life expectancy of HIV/AIDS patients to approach that of the general population. However, it remains unclear whether HIV infection affects the survival of lymphoma patients in the HAART era. METHODS: Patients diagnosed with Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), peripheral T-cell lymphoma (PTCL) or follicular lymphoma (FL) during 2004-2011 were identified from the National Cancer Database...
October 18, 2016: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/27756163/the-prognostic-value-of-bone-marrow-involvement-at-the-molecular-level-in-aggressive-lymphoma
#10
Neta Goldschmidt, Fares Darawshy, Geffen Kleinstern, Elena Slyusarevsky, Galina Pogrebijski, Svetlana Krichevsky, Dina Ben-Yehuda, Moshe E Gatt
We retrospectively studied the prognostic role of molecular (gene rearrangement, GRR) bone marrow (BM) involvement in diffuse large B-cell lymphoma (DLBCL, 424 patients) and in peripheral T-cell lymphoma (PTCL, 67 patients). When correlating BM GRR to histological findings at diagnosis, the GRR test was more sensitive (p = 0.036) but less specific (p < 0.0001) in PTCL than in DLBCL. For DLBCL (but not PTCL), a positive BM GRR correlated with advanced stage (p = 0.0001) and high IPI (p = 0...
October 18, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27754905/baseline-total-metabolic-tumor-volume-measured-with-fixed-or-different-adaptive-thresholding-methods-equally-predicts-outcome-in-peripheral-t-cell-lymphoma
#11
Anne-Segolene Cottereau, Sebastien Hapdey, Loic Chartier, Romain Modzelewski, Olivier Casasnovas, Emmanuel Itti, Herve Tilly, Pierre Vera, Michel A Meignan, Stéphanie Becker
: To compare in a large series of Peripheral T cell lymphoma (PTCL), as a model of diffuse disease, the prognostic value of baseline Total Metabolic Tumor Volume (TMTV) measured on FDG-PET/CT with adaptive thresholding methods to TMTV measured with a fixed 41% SUVmax threshold method. METHODS: 106 patients with PTCL, staged with a PET/CT were enrolled from 5 LYSA centers. In this series TMTV computed with the 41% SUVmax threshold is a strong predictor of outcome (Ann Oncol, 2016)...
October 6, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27739547/proton-switchable-vapochromic-behaviour-of-a-platinum-ii-carboxy-terpyridine-complex
#12
Atsushi Kobayashi, Shiori Oizumi, Yasuhiro Shigeta, Masaki Yoshida, Masako Kato
We synthesized a carboxy-substituted Pt(ii)-terpyridine complex, i.e. [PtCl(Hctpy)]Cl ([1H]Cl; Hctpy = 4'-carboxy-2,2':6',2''-terpyridine), that shows interesting switchable vapochromic behaviour upon protonation/deprotonation of the carboxy group. The as-synthesized dark-blue amorphous-like solid [1H]Cl·3H2O was converted to a yellow crystalline solid, [1H]Cl·H2O, upon exposure to various polar organic solvent vapours (e.g., acetonitrile, ethanol, 1-propanol, and dichloromethane), which promote the removal of water molecules...
October 14, 2016: Dalton Transactions: An International Journal of Inorganic Chemistry
https://www.readbyqxmd.com/read/27725924/burrowing-through-the-heterogeneity-review-of-mouse-models-of-ptcl-nos
#13
Christine E Cutucache, Tyler A Herek
Currently, there are 19 different peripheral T-cell lymphoma (PTCL) entities recognized by the World Health Organization; however, ~70% of PTCL diagnoses fall within one of three subtypes [i.e., peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma, and angioimmunoblastic T-cell lymphoma]. PTCL-NOS is a grouping of extra-thymic neoplasms that represent a challenging and heterogeneous subset of non-Hodgkin's lymphomas. Research into peripheral T-cell lymphomas has been cumbersome as the lack of defining cytogenetic, histological, and molecular features has stymied diagnosis and treatment of these diseases...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27719721/-t-bet-in-peripheral-t-cell-lymphoma
#14
Z Wang, D B Zhang, W Zhou
Objective: To evaluate the expression of transcription factor T-bet (T-box expressed in T cells) and explore its effects on prognosis in peripheral T-cell lymphoma (PTCL). Methods: This study included 109 previously untreated patients diagnosed with PTCL in the pathology system at Peking Union Medical College Hospital from 2007 to 2013. Formalin-fixed, paraffin-embedded blocks and clinical information of these patients were collected. T-bet expression was examined by immunohistochemical stain, while its relationship with clinical feature and prognosis was analyzed...
September 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/27711130/highly-diverse-efficacy-of-salvage-treatment-regimens-for-relapsed-or-refractory-peripheral-t-cell-lymphoma-a-systematic-review
#15
Ya-Ting Yang, Cheng-Jeng Tai, Chiehfeng Chen, Hong-Cheng Wu, Natalia Mikhaylichenko, Hsien-Tsai Chiu, Yun-Yi Chen, Yi-Hsin Elsa Hsu
BACKGROUND: The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. METHOD: The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL...
2016: PloS One
https://www.readbyqxmd.com/read/27690235/dnmt3a-is-a-haploinsufficient-tumor-suppressor-in-cd8-peripheral-t-cell-lymphoma
#16
Staci L Haney, G Michael Upchurch, Jana Opavska, David Klinkebiel, Ryan A Hlady, Sohini Roy, Samikshan Dutta, Kaustubh Datta, Rene Opavsky
DNA methyltransferase 3A (DNMT3A) is an enzyme involved in DNA methylation that is frequently mutated in human hematologic malignancies. We have previously shown that inactivation of Dnmt3a in hematopoietic cells results in chronic lymphocytic leukemia in mice. Here we show that 12% of Dnmt3a-deficient mice develop CD8+ mature peripheral T cell lymphomas (PTCL) and 29% of mice are affected by both diseases. 10% of Dnmt3a+/- mice develop lymphomas, suggesting that Dnmt3a is a haploinsufficient tumor suppressor in PTCL...
September 2016: PLoS Genetics
https://www.readbyqxmd.com/read/27677595/loss-of-dnmt3a-induces-cll-and-ptcl-with-distinct-methylomes-and-transcriptomes-in-mice
#17
Staci L Haney, Garland M Upchurch, Jana Opavska, David Klinkebiel, Adams Kusi Appiah, Lynette M Smith, Tayla B Heavican, Javeed Iqbal, Shantaram Joshi, Rene Opavsky
Cytosine methylation of DNA is an epigenetic modification involved in the repression of genes that affect biological processes including hematopoiesis. It is catalyzed by DNA methyltransferases, one of which -DNMT3A- is frequently mutated in human hematologic malignancies. We have previously reported that Dnmt3a inactivation in hematopoietic stem cells results in chronic lymphocytic leukemia (CLL) and CD8-positive peripheral T cell lymphomas (PTCL) in EμSRα-tTA;Teto-Cre;Dnmt3a(fl/fl); Rosa26LOXP(EGFP/EGFP) (Dnmt3a(Δ/Δ)) mice...
September 28, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27672541/development-of-chidamide-for-peripheral-t-cell-lymphoma-the-first-orphan-drug-approved-in-china
#18
REVIEW
Xianping Lu, Zhiqiang Ning, Zhibin Li, Haixiang Cao, Xinhao Wang
Peripheral T-cell lymphoma (PTCL) is a set of rare and highly heterogeneous group of mature T- and NK-cell neoplasms associated with poor outcomes and lack of standard and effective therapies. The total number of newly diagnosed cases of PTCL yearly in China is estimated about 50,000. Chidamide (CS055) is a novel and orally active benzamide class of histone deacetylase (HDAC) inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, the enzymes that are involved and play an important role in tumor initiation and development in both tumor cells and their surrounding micro-environment...
August 2016: Intractable & Rare Diseases Research
https://www.readbyqxmd.com/read/27648317/long-term-treatment-with-romidepsin-in-patients-with-peripheral-t-cell-lymphoma
#19
Claudius Irlé, Jonathan Weintraub
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas. Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of PTCL, and patients with AITL typically have a poor prognosis with limited treatment options. Clinical studies have demonstrated the activity of romidepsin, a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor, in patients with relapsed or refractory AITL. In the case presented herein, we describe a patient treated with single-agent romidepsin at first diagnosis of AITL, resulting in complete remission for over 2 years and leading to the use of maintenance dosing...
2016: Case Reports in Hematology
https://www.readbyqxmd.com/read/27626696/molecular-alterations-and-tumor-suppressive-function-of-the-dusp22-dual-specificity-phosphatase-22-gene-in-peripheral-t-cell-lymphoma-subtypes
#20
Pierre Mélard, Yamina Idrissi, Laetitia Andrique, Sandrine Poglio, Martina Prochazkova-Carlotti, Sabine Berhouet, Cécile Boucher, Elodie Laharanne, Edith Chevret, Anne Pham-Ledard, Andréa Carla De Souza Góes, Véronique Guyonnet-Duperat, Alice Bibeyran, François Moreau-Gaudry, Béatrice Vergier, Marie Beylot-Barry, Jean-Philippe Merlio, David Cappellen
Monoallelic 6p25.3 rearrangements associated with DUSP22 (Dual Specificity Phosphatase 22) gene silencing have been reported in CD30+ peripheral T-cell lymphomas (PTCL), mostly with anaplastic morphology and of cutaneous origin. However, the mechanism of second allele silencing and the putative tumor suppressor function of DUSP22 have not been investigated so far. Here, we show that the presence, in most individuals, of an inactive paralog hampers genetic and epigenetic evaluation of the DUSP22 gene. Identification of DUSP22-specific single-nucleotide polymorphisms haplotypes and fluorescence in situ hybridization and epigenetic characterization of the paralog status led us to develop a comprehensive strategy enabling reliable identification of DUSP22 alterations...
September 10, 2016: Oncotarget
keyword
keyword
47694
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"